Almost 50% of the cells infiltrating the central nervous system (CNS) of animals with experimental allergic encephalomyelitis (EAE) are macrophages (M(p) . To investigate the role of the M(p in the pathogenesis of EAE, we eliminated Mcp by means of mannosylated liposomes containing dichloromethylene diphosphonate (C12MDP) . C12MDP-containing liposomes injected intravenously eliminate M(p in spleen and liver. Incorporation of mannose into the lipid layers enables the liposomes to pass the blood-brain barrier (BBB). Injections of C12MDP-containing mannose liposomes intravenously shortly before the appearance of clinical signs, markedly suppressed the expression of clinical signs of EAE . This suppression was accompanied by a marked reduction of infiltrated M(p in the CNS. C12MDP-containing liposomes without mannose incorporated had no effect . C12MDP-containing mannosylated liposomes had no effect on plasma corticosterone levels compared with injections of saline; thus, the suppression of expression of EAE was not corticosterone mediated . These results show that the M(p within the CNS play an important role in the pathogenesis of EAE .
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Experimental allergic encephalomyelitis (EAE)t is an inflammatory demyelinating disease of the central nervous system (CNS), which can be induced in genetically susceptible animals by an injection of whole nervous tissue homogenate emulsified in CFA. On clinical and pathological grounds EAE is considered to represent an animal model for immuneinflammatory diseases of the CNS in general, and for multiple sclerosis (MS) in particular (1) . About 10-12 d after sensititation the animal starts to exhibit neurological signs caused by the effects of mononuclear cells infiltrating the CNS, forming perivascular cuffs. The invading cells mainly consist of T cells and macrophages (M(p) and to a lesser extent of B cells (2-5) .
EAE is considered to be a T cell-dependent, delayed type of hypersensitivity reaction . It is not clear, however, by which mechanism cell-mediated immunity initiates clinical and patho-logical expression of EAE. In a previous study we have shown that M(p are present in large numbers in the CNS of EAE animals (6) . It is very likely that these cells play a role in the development of tissue damage in the CNS and subsequent neurological disorders . M(p have been demonstrated to strip off myelin from axons (7) and to phagocytize myelin in a receptor-mediated way (8) . Furthermore, activated Mcp secrete numerous products that can play multiple roles in nonspecific inflammatory reactions underlying breakdown of the blood-brain barrier (BBB), the attraction of immunocompetent cells into the CNS, the activation of immunocompetent cells, the generation of edema, and degradation of myelin (9) . In vitro degradation of myelin by M p products such as neutral proteinases (10), oxygen radicals (11), and TNF (12) has been demonstrated . Blood monocytes of MS patients show an increased oxidative burst activity (13). Increased levels of proteinases are found in lesions of MS brains (14) and EAE CNS (15). Indeed, administration of both proteinase inhibitors (16, 17) and oxygen radical scavengers (18) , suppresses the expression of EAE or experimental allergic neuritis (EAN), the peripheral counterpart of EAE .
Depletion of macrophages after injection of silica dust shortly before and during the appearance of clinical signs in EAE (19) and EAN (20) (21) (22) , remarkably attenuates the de-velopment of the disease, which suggests that Map play a crucial role in the effector phase of the disease. Silica however, is known to exert additional effects on other immunocompetent cells (23) (24) (25) , and there is no evidence that silica is capable of passing the BBB. To bypass the side erects of silica we used an in vivo Mp elimination method, described by van Rooijen and van Nieuwmegen (26) . Map were eliminated by intravenous injections of liposomes constructed of phosphatidylcholine and cholesterol and containing dichloromethylene diphosphonate (C12MDP) (C12MDP PC-liposomes) . C12MDP PC-liposomes injected intravenously eliminate almost all Map in spleen and liver (26, 27) . Free C12MDP is not toxic; it needs enclosure in liposomes and subsequent phagocytosis is necessary for its toxic effect . Therefore, only phagocytes are susceptible (26) . To reach the CNS, we used mannosylated C12MDP PC-liposomes (C12MDP PCMANliposomes) . Mannosylated PC-liposomes are, in contrast with non-mannosylated PC-liposomes, capable of passing the BBB (28) . To cause the liposomes to reach the CNS at the moment the Map start to infiltrate, we injected the liposomes just before the expected expression of clinical signs. We found that C12MDP PCMAN-liposomes injected on days 8 and 10 postimmunization (p.i.) completely suppressed or markedly attenuated the expression of EAE. Non-mannosylated C12MDP PC-liposomes had no effect on expression of EAE. Timing of the liposome injections appeared to be critical .
Materials and Methods
Animals. Male Lewis rats were obtained from the Zentralinstitut fur Versuchstierzucht (Hannover, FRG), housed two to three animals per plastic cage, and kept under standard conditions, water and food available ad libitum . The animals had a weight of "180-200 g at the time of inoculation .
Induction ofEAE. Acute EAE was induced by a single subcutaneous injection under Hypnorm anesthesia Oanssen Pharmaceutica, Beerse, Belgium, i.m ., 0.5 ml/kg bodyweight) of 50,ul guinea pig spinal cord (GSC) homogenate in one hind food pad. This emulsion consisted of 1 g GSC in 1 ml saline (0.9%a, NaCI), to which 10 mg Mycobacterium tuberculosis H37 RA, (Difco Laboratories, Detroit, MI) in 1 ml CFA (Difco laboratories) was added.
Preparation ofLiposomes. Multilamellar liposomes were prepared as described (29) . Briefly, to prepare the PC-liposomes, 86 mg phosphatidylcholine and 8 mg cholesterol (Sigma Chemical Co ., St . Louis, MO) (molar ratio phosphatidylcholine/cholesterol = 6:1, with a total amount of 140 pmol of lipids) were dissolved in 10 ml chloroform in a 500-ml, round-bottomed flask, dried in vacuo on a rotary evaporator to form a film . Subsequently the film was dispersed into liposomes after the addition of PBS (0 .15 M NaCl in 10 mM phosphate buffer, pH 7.4). To enclose C12MDP into PC-liposomes, 1.89 g C12MDP (maximum soluble amount) was added to 10 ml PBS. the preparations were kept for 2 h at room temperature (RT) and sonicated for 3 min at 20°C in a sonicor (50 Hz) and kept at RT for another 2 h. The liposomes were centrifuged at 100,000 g for 30 min and finally resuspended in 4 ml PBS. To prepare PCMAN-liposomes, 70 .9 mg phosphatidylcholine and 10 .8 mg cholesterol were dissolved in 8 ml chloroform and added to 3.6 mg p-aminophenyl-a-D-mannopyranoside (Sigma Chemical Co., St . Louis, MO), dissolved in 2 ml methanol, dried 1026 Macrophages and Experimental Allergic Encephalomyelitis as described above. The molar ratio of phosphatidylcholine/cholesterol/mannoside of 7:2 :1 was chosen according to Umezawa and Eto (28) . The total amount of lipids was 140 pmol . The dried lipid film was dissolved in chloroform and dried once again before the aqueous phase, with or without C12MDP, was added. Liposomes were sonicated and centrifuged as described above. Treatment. Two experiments are described. In Exp. A timing of liposome injections is based on data on kinetics of Map movement into the CNS post-infection . Map start to infiltrate ± 8-10 d p.i . (6). Mannosylated liposomes are detected in the CNS 24-48 h post-injection (28) . Therefore, we gave a first injection of liposomes 8 d p.i ., followed 2 d later by a second injection. Three groups of eight rats each were treated with either 0.9% NaCl, PBS PCMAN-liposomes (two control groups), or with C12MDP PCMAN-liposomes 8 and 10 d p.i . (2 ml im.) . On day 10 p.i. some blood samples were taken to study the effect of the mannose liposomes on the circulating monocytes. On days 15-17 p.i . the animals were killed for histological examination . At this moment infiltrated Map are abundantly present in the CNS of EAE rats .
Exp. B was constructed to study (a) effects of Map elimination at different stages during the induction phase and early effector phase of the disease, and (b) effects on the expression of EAE after elimination of Map in spleen and liver by C12MDP PC-liposomes, which were not mannosylated and not capable of passing the BBB (30) . This experiment consisted of four groups of five rats each which received two intravenous injections of 2 ml C12MDP PCMAN-liposomes on days 6 and 8, 7 and 9, and 8 and 10 p.i ., or two intravenous injections of 2 ml C12MDP PC-liposomes on days 8 and 10 p.i . The control group in this experiment consisted of six rats and received no treatment post-immunization. On day 50 p.i . the animals were killed for histological evaluation .
Clinical Assessment. The rats were weighed and investigated daily to score the development of neurological signs. Clinical signs were scored from 0 to 4: 0, no clinical signs; 1, loss of tail tonus and unsteady gait (partial loss of tail tonus was scored only when registered on two consecutive days); 2, paresis of the hind legs ; 3, complete paralysis of the hind legs or complete lower part of the body ; 4, death due to EAE. 2 and 3 are often accompanied by urinary and fecal incontinence (31) .
Histological Techniques. Animals were anesthetized with hypnorm (i .m ., 1 ml/kg bodyweight) and killed by an intracardial injection of 0.5 ml nembutal (Algin BY, Maassluis, The Netherlands) . Brain, optic nerves, spinal cord, liver, and spleen were dissected and frozen in liquid nitrogen and stored at -20 or -70°C. Cryostat sections of 8 I= were cut serially, picked up on glass slides, and dried in a container with silica gel. Immunocytochemistry was applied to examine cellular infiltrates in the CNS and efficacy of Map elimination by the C12MDP-liposomes in spleen and liver. The following mAbs were used: mouse anti-pan-T cell (OX-19), mouse anti-la (OX-4), both from Serotec, Oxford, UK ; mouse anti-rat macrophages (ED1 and ED3) (32) ; and the mAb ED8 which recognizes rat Map as well as glial cells (33, 34) . ED8 shows a staining pattern comparable with OX-42, which recognizes the iC3b receptor (35) . As conjugate a rabbit anti-mouse IgGtiperoxidase (Dako, Tilburg, The Netherlands) was used . Antibodies and conjugate were diluted in 0.01 M PBS (pH 7.4) with 0.2% BSA (Organon Technika, Oss, The Netherlands) and used in dilutions between 1:100 and 1:400 . All incubations were carried out horizontally at RT. After incubation with the first antibody for 45 min, the slides were rinsed in PBS, incubated in conjugate with 1% normal rat serum for 30 min, and washed again in PBS. Peroxidase activity was demonstrated after a 10-min incubation with 0.5 mg/ml 3,3'-diaminobenzidine-tetra-hydrochloride (DAB; Sigma days post immunization Chemical Co .) in 0.05 M Tris buffer, pH 7.6, containing 0.03% H202 . Sections were lightly counterstained with hematoxylin.
Bloodsmears of animals treated with liposomes were air dried and stained with May Grunwald-Giemsa dyes (Merck, Darmstadt, FRG), according to standard histological staining methods.
Determination of Effects of C12MDP PCMAN-Liposomes on
Plasma Corticosteroid Levels. To exclude the possibility that the effect of treatment of EAE was caused by the induction of a stress response in the CNS by the PCMAN liposomes and a concomitant rise in plasma corticosterone levels, we studied the effect of man-, nosylated liposomes on plasma corticosterone levels. I.ewis rats were injected intravenously with either 2 ml 0.9% NaCl or 2 ml C12MDP PCMAN-liposomes. Blood was collected from the tail at 6, 24, 48, and 72 h after the injections, kept on ice in heparincontaining tubes, centrifuged (100 g, 15 min; 4°C) and stored at -20°C until use. Blood was collected within 5 min after the beginning of an ether anesthesia to prevent elevation of corticosterone levels due to ether stress . Ether causes plasma corticosterone levels to rise up to 60 lAg/100 ml plasma after 20 min (36, 37) . Plasma corticosterone was measured using an extraction step with dichloromethane followed by a fluorometric determination as described (38) . and 2, respectively. 0.9% NaCl and PBS PCMAN-liposome-treated animals expressed EAE as normal, showing the first neurological signs on day 9.8 ± 0.7 and day 10.8 ± 0.6 p.i . respectively. Clinical signs were spotted until days 14-17 p.i . ; the exact duration can not be given, since 50% of the animals were still having clinical signs when animals were killed for histological evaluation. Clinical signs included flaccid tail and paresis of the hindlegs. In contrast, all animals that received C12MDP PCMAN-liposomes showed a striking absence of neurological disorders. Weight loss was 1027 Huitinga et al.
apparent in all three groups, though animals in the C12MDR and PBS PCMAN-liposome group lost a little less weight than animals in the saline-treated group (difference not statistically significant) (Fig. 2) . were only sparsely seen outside the blood vessels (Fig.' 3 b) . This phenomenon was not observed in lesions of saline and PBS PCMAN-liposome treated animals (Fig. 3 a) . No changes in glial cell populations could be observed; in particular no differences were observed in the morphology and number of ED8+ glial cells of the different experimental groups. Spleen and liver sections showed efficient elimination of the M(p by the C12MDP PC-and C12MDP PCMANliposomes as described before (27) . Blood samples collected on day 10 p .i. (2 d after the first injection), _showed an increase in the ratio of PMN to lymphocytes . Percentages PMN ranged from normally 11% in healthy Lewis rats to 39% in the saline treated, 22% in the PBS PCMAN-liposome, and 34% in the ClzMDP PCMAN-liposome treated group (Fig.  4) . Percentages are given of counts of 200 white blood cells per animal . Expanded and vacuolized monocytes made up 8% of the C12MDP PCMAN-liposome and 2.5% of the PBS PCMAN-liposome-treated animals . Such enlarged and sometimes disintegrating monocytes were not spotted in healthy Lewis rats or saline-treated EAE rats. Percentages of healthy looking monocytes varied between 2% in healthy Lewis rats, to 3% in the saline-, 7% in the PBS PCMANliposome-, and 2 .5% in the C12MDP PCMAN-liposometreated EAE group.
EAE-Experiment B
Clinical Data. The effect of C12MDP PCMAN-liposomes injected at three different time points (days 6 and 8, 7 and 9, and 8 and 10 p.i.) and of C12MDP PC-liposomes (days 8 and 10 p.i.) on the expression of clinical signs of EAE is shown in Fig. 5 and Table 1 . Animals were observed until day 50 p.i . The control group in this experiment received no treatment (2-ml i .v. injections of saline at days 8 and 10 p .i. have no effect on expression of EAE; unpublished data) .
First signs of EAE (flaccid tail) were spotted 9 .4 ± 1 .3 d p .i. in the C12MDP PC-liposome-treated group, subsequently followed by the control animals (10 .2 ± 0 . . Experiment A : Effect of EAE, 2 ml 0.9% NaCl, 2 ml PBS containing PCMAN-liposomes, and 2 ml C12MDP containing PCMANliposomes, injected ix., days 8 and 10 p.i ., on the ratio lymphocytes :PMN :monocytes of the Lewis rat . Blood samples were taken 10 days p.i ., this was two days after a first ix. injection of 2 ml saline or liposomes. Blood smears were stained with May Granwald-Giemsa and 200 leucocytes per smear were identified on morphological features and counted. The average ratio of each experimental group ± SD is represented. Note the increase in ratio PMNaymphocytes in EAE animals and the increase in ratio monocytesAymphocytes in the PBS PCMAN-liposomes treated animals, and the appearance of the group enlarged and vacuolized monocytes. Difference with healthy Lewis rats is statistical significant: " = p < 0.01 (Wilcoxon Rank sum Test) .
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Huitinga et al . (Table 1) . Thus, there was a correlation between the timing of the injections of C12MDP PCMAN-liposomes and the day of onset of clinical disease . Severity of the disease was analyzed based on the number of animals that had at least paresis of hindlegs (score 2). It appeared that C12MDP PCMAN-liposomes injected 7 and 9 d or 8 and 10 d p.i. had the best suppressive effects on expression of clinical signs of EAE (p < 0.05). Incidence of clinical disease was 60% in these groups, but signs were restricted to flaccid tails for only a maximum of 3 d . Based on the incidence of one relapse in the days 7 and 9 group and on the total number of days during which flaccid tails (score 1) were scored, EAE in the days 8 and 10 group was even better suppressed than in the days 7 and 9 group. EAE was also suppressed in animals that received C12MDP PCMAN-liposomes 6 and 8 d p.i ., but two relapses occurred and paresis of the hindlegs occurred during 10 d against 1 d in each of the other two C12MDP PCMAN-liposome-treated groups (Fig. 5) . In contrast, animals that were treated with C12MDP PC-liposomes all developed EAE. Mean day of onset of clinical disease was, as already mentioned, one day before that of the controls. Two of five animals did not recover as quickly as animals in the other experimental groups .
One relapse occurred and one animal died due to EAE. Weight loss was apparent in all five experimental groups and comparable to the weight loss seen during EAE in Exp. A (Fig. 2) . Histological Evaluation . Nervous tissue collected 50 d p .i . showed dim remainders of multiple lesions . Lesions in animals of all experimental groups showed only a very small amount of infiltrating cells . Pan -T cells were present in some lesions as were ED1 and very sparse numbers of ED3+ cells. Comparison of central nervous tissue of untreated and liposometreated groups revealed no difference in the amount of lesions and infiltrating panT cells. ED1+ and ED3+ cells, however, showed a tendency to be present in higher numbers in animals in which the disease had been most strongly suppressed . Histological evaluation of spleen sections did not reveal signs of Mcp eliminating activities 6 wk before dissection . ED1+ and ED3+ cells were present as normal . Recovery within 2 mo of M<p in the spleen after depletion by C12MDP-containing liposomes has been described (27) .
Effect of C12MDP PCMAN-Liposomes on Plasma Corticosterone Levels
No difference was observed between the effect of injection of C12MDP PCMAN liposomes and injection of saline on the plasma corticosterone levels (Fig. 6) . Plasma corticosterone levels were in both groups slightly elevated up to 10-18 Fig/ 100 ml plasma until 3 d after the injections. Basic levels were 4 .0 ± 1 .1 and 4.5 ± 1 .4 ug corticosterone/100 ml plasma, respectively. The elevation after the injections is probably caused by stress reactions due to the injections and repetition of blood sampling, and is similar in both groups .
Discussion
The results clearly demonstrate that Lewis rats can be protected against development of neurological signs of EAE by intravenous injections of mannosylated C12MDP PC-liposomes shortly before onset of clinical signs. No significant effect was found on weight loss normally accompanying expression of EAE. Radioactive labeled mannosylated PCliposomes can be demonstrated in the CNS after intraperitoneal injection (28) . This is in contrast with radiolabeled nonmannosylated PC-liposomes, which can not be detected in the CNS after intravenous injection (30) . Both kinds of liposomes, when containing C12MDP, eliminated Mp in spleen liver when injected intravenously (27 ; this study) . C12MDP PC-liposomes without mannose incorporated had no effect on the expression of EAE . Elimination of M(p in spleen and liver was apparently not sufficient to suppress clinical signs of EAE . The suppressive effect of the C12MDP PCMANliposomes is therefore likely to be due to elimination of Mrp infiltrating the CNS. In contrast to silica (23) (24) (25) , C12MDP PC-liposomes selectively kill phagocytizing cells (29) and do not affect proliferation and functions of T and B cell clones in vitro (39) . Suppression of EAE by C12MDRcontaining liposomes is thus due to direct or indirect effects of M<p elimination .
Histological evaluation of CNS tissue revealed a considerable reduction of the number of infiltrated M(p in C1 2 MDP PCMAN-liposome-treated animals . This finding supports the fact that the mannosylated PC-liposomes reach the CNS and exert their effect there. On light microscopal level no changes in glial cell populations could be observed .
Recent intriguing data on involvement of corticosteroids in immune-regulatory events show the need of elevated plasma corticosterone levels for spontaneous recovery of rats from EAE (40, 41) . To rule out the possibility that the C12MDP PCMAN-liposomes evoke a stress response in the CNS by stimulating the hypothalamic-pituitary-adrenal axis and subsequently suppress expression of EAE by elevation of corticosterone levels, we studied the effect of intravenous injections 1031 Huitinga et al .
Of C12MDP PCMAN-liposomes on plasma corticosterone levels. No difference in effect was observed on corticosterone levels between saline and C12MDP PCMAN-liposome injections. Slight elevations, probably due to the stress induced by the injections and repetition of blood sampling under ether anesthesia were observed, but did not reach corticosteroid levels of more then 30-40 jig/100 ml, which are described to be necessary for EAE recovery (40) . Timing of the injections appeared, to be very important . Suppression of EAE after C12MDP PCMAN-liposomes injected 6 and 8 d p.i. was not as strong as after C12MDP PCMAN-liposome injections 7 and 9 and 8 and 10 d p.i. Injections of C12MDP PCMAN-liposomes on two successive days post-immunization showed an almost constant time interval of 3 d between the day of the second injection and the day of onset of clinical signs ( (43, 44) and MRC OX42 (35) . It must be noted, however, that neither W3/25 nor OX-42 are specific M(p markers, nor do they recognize all Map as does mAb ED1, for example (32, 35, 43, 44) . Therefore, it is possible that the Mrp in the lesions of the CNS of the irradiated rats were not recognized by the used mAbs. Another explanation for the discrepancy between the results of Sedgwick et al . (42) and our results is that the mechanism that causes paralysis in the irradiated rats differs from that in unirradiated rats . The pathology in the CNS of irradiated rats includes, in contrast to the usual EAE models, hemorrhages that also can cause paralysis. A third possibility is that the effect of Map elimination in our study is not caused directly by the lack of M(p but by the lack of their stimulatory activity for CD4 + cells. Our immunohistochemical findings reveal no difference in the number and localization of T cells in the CNS between animals treated with C12MDP PCMAN-liposomes and controls .
The difference between the effects of mannosylated and non-mannosylated C12MDP PC-liposomes was striking. Mannosylated liposomes are found to pass the BBB (28). It is not clear how the liposomes pass the BBB, and Umezawa and Eto (28) mention mannose as being a "recognition marker" for an unknown molecule or mechanism. With respect to the present study, it should be kept in mind that a mannosyl receptor can be expressed on activated monocytes (45, 46) . This phenomenon leads to a more efficient in vitro binding of mannosylated liposomes to macrophages (47) . However, both kinds of liposomes, with and without mannose incorporated, eliminate Map in spleen and liver equally well after intravenous injections . In addition, i.v. injections of 2 ml of C12MDP PCMAN-as well as C12MDP PC-liposomes eliminate all monocytes in the blood (Huitinga, I., J.G .M .C . Damoiseaux, N. Van Rooijen, and C.D. Dijkstra, manuscript submitted for publication) . Elimination of M<p in spleen and liver and monocytes in the blood, was apparently not sufficient to suppress EAE. This raises the question why silica dust suppresses EAN (20) (21) (22) and EAE (19) . Possible explanations are the following: (a) silica exerts additional effects on other References 2.
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8. immunocompetent cells (23) (24) (25) , (b) silica is capable of entering the CNS, and (c) silica is more efficient in eliminating Mrp than are the C12MDP PC-liposomes .
In conclusion, the results of our study show that Mip play an important role in the pathogenesis of neurologic disorders in the CNS of EAE animals. As long as the cause of demyelinating disease like MS is uncertain, modulation of effector mechanisms as seen in animal models for demyelinating diseases such as EAE, is of interest. The M(p seem to be an interesting target, and apparently can be reached and influenced within the CNS by using the appropriate liposomes. Studies are underway to determine which specific functions of activated Mrp are involved in the pathogenesis of EAE.
